Amyris (AMRS) Tops Q4 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amyris (AMRS) to acquire Costa Brazil
March 1, 2021 8:13 AM ESTAmyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, announces that it has entered into an agreement to acquire Costa Brazil. Amyris is accelerating its growth and market leadership in clean beauty with the addition of Costa Brazil to its family of consumer brands, including Biossance®, Pipette®, Rose Inc., JVN, and Terasana.
Co-founded by Francisco Costa and Michele Levy, Costa Brazil is a clean luxury beauty and wellness brand inspired by... More
Roth Capital Starts Amyris, Inc. (AMRS) at Buy
February 26, 2021 8:15 AM ESTRoth Capital analyst Craig Irwin initiates coverage on Amyris, Inc. (: AMRS) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Amyris, Inc. click here. For more ratings news on Amyris, Inc. click here.
Shares of Amyris, Inc. closed at $9990.72 yesterday.
... More